PURPOSE: Acquired somatic uniparental disomy (UPD) is commonly observed in myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), or secondary acute myelogenous leukemia (sAML) and may point toward genes harboring mutations. Recurrent UPD11q led to identification of homozygous mutations in c-Cbl, an E3 ubiquitin ligase involved in attenuation of proliferative signals transduced by activated receptor tyrosine kinases. We examined the role and frequency of Cbl gene family mutations in MPN and related conditions. METHODS: We applied high-density SNP-A karyotyping to identify loss of heterozygosity of 11q in 442 patients with MDS, MDS/MPN, MPN, sAML evolved from these conditions, and primary AML. We sequenced c-Cbl, Cbl-b, and Cbl-c in patients with or without corresponding UPD or deletions and correlated mutational status with clinical features and outcomes. RESULTS: We identified c-Cbl mutations in 5% and 9% of patients with chronic myelomonocytic leukemia (CMML) and sAML, and also in CML blast crisis and juvenile myelomonocytic leukemia (JMML). Most mutations were homozygous and affected c-Cbl; mutations in Cbl-b were also found in patients with similar clinical features. Patients with Cbl family mutations showed poor prognosis, with a median survival of 5 months. Pathomorphologic features included monocytosis, monocytoid blasts, aberrant expression of phosphoSTAT5, and c-kit overexpression. Serial studies showed acquisition of c-Cbl mutations during malignant evolution. CONCLUSION: Mutations in the Cbl family RING finger domain or linker sequence constitute important pathogenic lesions associated with not only preleukemic CMML, JMML, and other MPN, but also progression to AML, suggesting that impairment of degradation of activated tyrosine kinases constitutes an important cancer mechanism.
PURPOSE: Acquired somatic uniparental disomy (UPD) is commonly observed in myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), or secondary acute myelogenous leukemia (sAML) and may point toward genes harboring mutations. Recurrent UPD11q led to identification of homozygous mutations in c-Cbl, an E3 ubiquitin ligase involved in attenuation of proliferative signals transduced by activated receptor tyrosine kinases. We examined the role and frequency of Cbl gene family mutations in MPN and related conditions. METHODS: We applied high-density SNP-A karyotyping to identify loss of heterozygosity of 11q in 442 patients with MDS, MDS/MPN, MPN, sAML evolved from these conditions, and primary AML. We sequenced c-Cbl, Cbl-b, and Cbl-c in patients with or without corresponding UPD or deletions and correlated mutational status with clinical features and outcomes. RESULTS: We identified c-Cbl mutations in 5% and 9% of patients with chronic myelomonocytic leukemia (CMML) and sAML, and also in CML blast crisis and juvenile myelomonocytic leukemia (JMML). Most mutations were homozygous and affected c-Cbl; mutations in Cbl-b were also found in patients with similar clinical features. Patients with Cbl family mutations showed poor prognosis, with a median survival of 5 months. Pathomorphologic features included monocytosis, monocytoid blasts, aberrant expression of phosphoSTAT5, and c-kit overexpression. Serial studies showed acquisition of c-Cbl mutations during malignant evolution. CONCLUSION: Mutations in the Cbl family RING finger domain or linker sequence constitute important pathogenic lesions associated with not only preleukemic CMML, JMML, and other MPN, but also progression to AML, suggesting that impairment of degradation of activated tyrosine kinases constitutes an important cancer mechanism.
Authors: A John Iafrate; Lars Feuk; Miguel N Rivera; Marc L Listewnik; Patricia K Donahoe; Ying Qi; Stephen W Scherer; Charles Lee Journal: Nat Genet Date: 2004-08-01 Impact factor: 38.330
Authors: Stefan Fröhling; Daniel B Lipka; Sabine Kayser; Claudia Scholl; Richard F Schlenk; Hartmut Döhner; D Gary Gilliland; Ross L Levine; Konstanze Döhner Journal: Blood Date: 2006-02-01 Impact factor: 22.113
Authors: Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland Journal: Cancer Cell Date: 2005-04 Impact factor: 31.743
Authors: E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green Journal: Lancet Date: 2005 Mar 19-25 Impact factor: 79.321
Authors: Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda Journal: N Engl J Med Date: 2005-04-28 Impact factor: 91.245
Authors: M A Murphy; R G Schnall; D J Venter; L Barnett; I Bertoncello; C B Thien; W Y Langdon; D D Bowtell Journal: Mol Cell Biol Date: 1998-08 Impact factor: 4.272
Authors: Sarah Abu Kar; Anna Jankowska; Hideki Makishima; Valeria Visconte; Andres Jerez; Yuka Sugimoto; Hideki Muramatsu; Fabiola Traina; Manuel Afable; Kathryn Guinta; Ramon V Tiu; Bartlomiej Przychodzen; Hirotoshi Sakaguchi; Seiji Kojima; Mikkael A Sekeres; Alan F List; Michael A McDevitt; Jaroslaw P Maciejewski Journal: Haematologica Date: 2012-07-06 Impact factor: 9.941
Authors: Scott Nadeau; Wei An; Nick Palermo; Dan Feng; Gulzar Ahmad; Lin Dong; Gloria E O Borgstahl; Amarnath Natarajan; Mayumi Naramura; Vimla Band; Hamid Band Journal: Biochem Anal Biochem Date: 2012-07-30
Authors: Ramon V Tiu; Lukasz P Gondek; Christine L O'Keefe; Paul Elson; Jungwon Huh; Azim Mohamedali; Austin Kulasekararaj; Anjali S Advani; Ronald Paquette; Alan F List; Mikkael A Sekeres; Michael A McDevitt; Ghulam J Mufti; Jaroslaw P Maciejewski Journal: Blood Date: 2011-02-01 Impact factor: 22.113
Authors: F Traina; V Visconte; P Elson; A Tabarroki; A M Jankowska; E Hasrouni; Y Sugimoto; H Szpurka; H Makishima; C L O'Keefe; M A Sekeres; A S Advani; M Kalaycio; E A Copelan; Y Saunthararajah; S T Olalla Saad; J P Maciejewski; R V Tiu Journal: Leukemia Date: 2013-09-18 Impact factor: 11.528